Relationship between screening plasma glucose concentrations and cancer- and all-cause mortality: the Jichi Medical School (JMS) cohort study

Abstract

Aim Whether plasma glucose concentrations at the screening level in the public health care setting can predict mortality remains to be determined in Japanese people. The aim of this study was to investigate the relationships between screening plasma glucose concentrations and cause-and all-cause mortality in a general Japanese cohort.Subjects and methods The current study investigated 11,998 community-dwelling participants from 12 Japanese communities who had been registered in the Jichi Medical School Cohort Study (a population-based prospective cohort study) between 1992 and 1995. Mortality was documented as the primary outcome. The relationships between screening plasma glucose concentrations and outcomes were analyzed using Cox proportional hazard models. Results In all, 1,050 deaths (men/women = 631/419) were identified during a follow-up period of 10.7 years. Compared with the lowest glucose concentration (<5.22 mmol/L), multivariate-adjusted hazard ratios for the highest glucose concentration (≥6.11 mmol/L) were 1.52 (95 % confidence interval [CI], 1.25-1.85) for all-cause mortality and 1.76 (95 % CI, 1.29-2.41) for cancer-cause mortality in men and 4.65 (95 % CI, 1.69-12.78) for myocardial infarction mortality in women. ConclusionsThe current Japanese population-based cohort study suggests that high screening plasma glucose concentrations can predict cancer-and all-cause mortality, particularly in men.

The ratio of fasting plasma glucose to hemoglobin A1c as a predictor of all-cause mortality in individuals with normal glucose levels: The Jichi Medical School cohort study

“…In assuming 13% of the incidence rate (approximately 11 years) of all-cause deaths and 2.0 of the risk ratio (in a low-risk group versus high-risk group) in men (with a reference to a study by Kakehi et al 16 ), the sample size was estimated to be 150 subjects in each group with the alpha-level = 0.05 (5%) and beta-level = 0.20 (power: 80%; two-tailed). Similarly, in assuming 6% of the incidence rate of all-cause deaths and 2.0 of the risk ratio (in a low-risk group versus high-risk group) in women (with a reference to a study by Kakehi et al 16 ), the sample size was estimated to be 350 subjects in each group. The power analyses were carried out using StatMate 3.0 for Windows (ATMS Co, Ltd, Tokyo, Japan).…”

“…This study was conducted as an analysis of fractional population with normal FPG for evaluating the FPG/HbA1c ratio in particular (the aim of this study was different from that of the previous work). 16 Included in the study were 1404 participants of the original cohort who had their FPG and HbA1c levels measured. 15 The normal FPG levels were defined as <6.11 mmol/L in this study.…”